Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Free Cash Flow (2023 - 2025)

CG Oncology (CGON) has disclosed Free Cash Flow for 3 consecutive years, with -$36.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 73.48% year-over-year to -$36.2 million, compared with a TTM value of -$132.4 million through Dec 2025, down 67.75%, and an annual FY2025 reading of -$132.4 million, down 67.75% over the prior year.
  • Free Cash Flow was -$36.2 million for Q4 2025 at CG Oncology, up from -$39.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$8.0 million in Q1 2023 and bottomed at -$39.0 million in Q3 2025.
  • Average Free Cash Flow over 3 years is -$21.4 million, with a median of -$18.5 million recorded in 2024.
  • The sharpest move saw Free Cash Flow crashed 225.87% in 2024, then fell 12.56% in 2025.
  • Year by year, Free Cash Flow stood at -$14.6 million in 2023, then crashed by 42.51% to -$20.9 million in 2024, then plummeted by 73.48% to -$36.2 million in 2025.
  • Business Quant data shows Free Cash Flow for CGON at -$36.2 million in Q4 2025, -$39.0 million in Q3 2025, and -$28.0 million in Q2 2025.